Acute disseminated encephalomyelitis with bilateral optic neuritis following ChAdOx1 COVID-19 vaccination

BMC Neurol. 2022 Feb 12;22(1):54. doi: 10.1186/s12883-022-02575-8.

Abstract

Background: Acute disseminated encephalomyelitis (ADEM) is a rare immune-mediated inflammatory demyelinating disease of the central nervous system. We report a case of ADEM presenting with bilateral optic neuritis temporally associated with the ChAdOx1 vaccine against SARS-COVID19 virus.

Case presentation: A 36-year-old female presented with bilateral optic neuritis following her first dose of the ChAdOx1 vaccine. Initial MRI Brain showed evidence of demyelination within the subcortical white matter, with no radiological involvement of the optic nerves. Visual evoked potentials were consistent with bilateral optic neuritis which was confirmed radiologically on follow up MRI. She was treated with intravenous steroids with improvement both in symptoms and radiological appearance. A pseudo-relapse occurred which was treated with a further course of intravenous steroids followed by an oral taper. The clinical, radiological and serological results were most consistent with diagnosis of ADEM.

Conclusions: ADEM is an exceedingly rare complication of ChAdOx1 vaccine despite millions of doses. While it is imperative clinicians remain aware of neurological complications of vaccines, the importance of vaccination to control a pandemic should not be undermined.

Keywords: Acute disseminated encephalomyelitis; Case report; Demyelination; Oxford Astra Zeneca coronavirus disease 2019 vaccine; Severe acute respiratory syndrome coronavirus 2.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • COVID-19 Vaccines
  • COVID-19*
  • Encephalomyelitis, Acute Disseminated* / diagnostic imaging
  • Encephalomyelitis, Acute Disseminated* / drug therapy
  • Encephalomyelitis, Acute Disseminated* / etiology
  • Evoked Potentials, Visual
  • Female
  • Humans
  • Optic Neuritis* / drug therapy
  • Optic Neuritis* / etiology
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines